Cabozantinib shows intriguing activity in heavily pretreated urothelial carcinoma: Objective responsive rate of 19% observed in cohort of patients with metastatic UC

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Broderick, Jason M.
  • Source:
    Urology Times. September, 2020, Vol. 48 Issue 9, p22, 2 p.